Navigation Links
Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
Date:1/7/2008

Company plans to begin Phase IIb study in the first half of 2008

HOPKINTON, Mass., Jan. 7 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc., (Nasdaq: ALSE), announced today that it has concluded enrollment in the Phase I/IIa clinical trial of Cethrin in acute spinal cord injury (SCI). A total of 48 subjects have been enrolled at 9 sites in the United States and Canada. We expect to release periodic updates of the data in 2008 following protocol-specified patient evaluations.

"We continue to be encouraged by the safety and efficacy observations of the trial. The rate and magnitude of improvement of many subjects seems greater than the expected pattern of recovery," commented Dr. Mark Hurtt, Alseres Chief Medical Officer. "The findings of the Phase I/IIa study serve as a strong foundation for the acceleration of our development plans for Cethrin."

Alseres intends to move forward with its previously announced plans for the placebo-controlled, Cethrin Phase IIb trial in acute spinal cord injury at sites in the U.S., Canada, Europe and other countries in 2008. "We believe that Cethrin continues to be the most advanced drug candidate in the clinic for the treatment of acute spinal cord injury in the world. If approved, Cethrin may offer hope for the nearly 11,000 new cases annually in the U.S. alone whose healthcare costs in the first year post-injury exceed $4 Billion," noted Dr. Mark Pykett, President and COO of Alseres. "We are pleased that the enrollment of the Phase I/IIa trial has concluded. Interim reported data have demonstrated encouraging safety and efficacy results over a 30-fold dose range. We look forward to the initiation of the Phase IIb trial in the first half of 2008."

Cethrin contains a prop
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
2. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
11. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... WASHINGTON , July 22, 2014  Edwards Lifesciences ... in the science of heart valves and hemodynamic monitoring, ... Mussallem today served as an expert panelist at ... Committee,s Subcommittee on Health to discuss medical device innovation ... Barriers to Ongoing Evidence Development and Communication." ...
(Date:7/22/2014)...  Decision Resources Group finds that the market for interventional ... remain relatively stagnant at a value of around $80 million ... intervention (PCI) volumes are growing faster in Canada ... the United States and Europe ... increase in penetration of PCI procedures relative to coronary artery ...
(Date:7/22/2014)... -- The number of people overdosing from opioid prescription ... percent of the workforce has misused prescription painkillers, according ... making opioid use a serious threat to employee safety. ... correct dosage with a valid prescription, subtle impairment may ... Safety Council released a guide for employers, ...
Breaking Medicine Technology:Edwards' CEO Invited To Address Congress On Opportunities To Revitalize Medical Device Innovation 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 35 things employers should know about prescription painkiller use 25 things employers should know about prescription painkiller use 3
... Corporation (Nasdaq: DNDN ) today reported results for ... quarter ended September 30, 2010 was $20.2 million compared to ... the nine months ended September 30, 2010 was $23.1 million ... 2009.   Revenue from sales of PROVENGE® (sipuleucel-T) ...
... EMERYVILLE, Calif., Nov. 3, 2010 Onyx Pharmaceuticals, ... results for the third quarter 2010. Onyx reported non-GAAP net ... the third quarter 2010 compared to non-GAAP net income of ... period in 2009. Non-GAAP net income excludes, among other items, ...
Cached Medicine Technology:Dendreon Reports Third Quarter 2010 Financial Results 2Dendreon Reports Third Quarter 2010 Financial Results 3Dendreon Reports Third Quarter 2010 Financial Results 4Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 2Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 3Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 4Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 5Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 6Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 7Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 8Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 9Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 10
(Date:7/23/2014)... 2014 Follow us on LinkedIn ... pandemic proportions in both developed and developing countries alike. ... habits, growing preference for processed food, and sedentary lifestyles ... not regarded a disease by itself, obesity is known ... as diabetes, hypertension, cardiovascular risks as well as cancer. ...
(Date:7/23/2014)... 2014 Follow us on ... in the marketing mix, with its benefits ranging ... customers’ purchase decision. In a competitive market environment, ... packaging provides ample opportunities for sales growth. Manufacturers ... technologies such as blister and other high visibility ...
(Date:7/23/2014)... Hemodialysis equipment is the most widely used ... acute or chronic renal failure. , The Chinese hemodialysis ... European, American and Japanese enterprises. In 2013, the import ... growing demand for hemodialysis equipment in China, its import ... in 2009-2013. Germany, Sweden and Japan as the main ...
(Date:7/23/2014)... July 23, 2014 Throughout the month of ... announced plenty of new items. Also, it is hosting a ... unveiled its collection of short summer beach wedding dresses ... of popular styles in it. Additionally, these outfits are now ... , “As one of the world’s leading suppliers, LunaDress ...
(Date:7/23/2014)... Upland, California (PRWEB) July 23, 2014 ... flavorful home-delivered fully prepared healthy gourmet cuisine, received rave ... at the LA’s Largest Mixer. Mixer attendees were amazed ... Thursday, July 17th 2014, World Gardens Café, the premier ... gourmet cuisine, had a booth at Dave Linden’s LA’s ...
Breaking Medicine News(10 mins):Health News:Surging Obesity Rates Drives Demand for Bariatric (Obesity) Surgical Devices, According to New Report by Global Industry Analysts, Inc. 2Health News:Surging Obesity Rates Drives Demand for Bariatric (Obesity) Surgical Devices, According to New Report by Global Industry Analysts, Inc. 3Health News:Surging Obesity Rates Drives Demand for Bariatric (Obesity) Surgical Devices, According to New Report by Global Industry Analysts, Inc. 4Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 4Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 2Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 3Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 4Health News:LunaDress Continues To Enrich Product Line By Offering Short Summer Beach Wedding Dresses 2Health News:Healthy Food Gets Rave Reviews at LA’s Largest Mixer 2
... for growing mental health issues in the U.S. & ... (FBN) announces the launch of a new web ... resource for individuals who need support for and information ... mission is to provide an informative, supportive community supplemented ...
... Nichols Institute Diagnostics, Pleads Guilty to Felony Misbranding ... its subsidiary, Nichols Institute Diagnostics (NID), have entered ... to resolve criminal and civil claims concerning various ... marketed and sold to laboratories throughout the country ...
... the April 16 issue of the journal "Neuron," was conducted ... the Stanford University School of Medicine, who characterized their finding ... , ... (Vocus) April 15, 2009 -- ...
... April 15 TopBestPennyStocks.com is pleased to ... are interested in stocks on the move and in the news ... http://www.TopBestPennyStocks.com Today,s focused alerts include: ChinaCast Education (Nasdaq: ... VM ), Netflix Inc. (Nasdaq: NFLX ), Pfizer Inc. ...
... the disease, , , WEDNESDAY, April 15 (HealthDay News) ... the tracking of changes in cancer cells, according ... Medicine. , The technology uses specially designed dye-containing ... or on a single cell. , Current single-flow ...
... invasive surgical techniques -- most notably, laparoscopy -- ... option across the United States for people with ... newer, third option is a hybrid -- hand-assisted ... effective and compares favorably with standard laparoscopy, according ...
Cached Medicine News:Health News:Feel Better Network Launches Web Site for Relief in Challenging Times 2Health News:Quest Diagnostics to Pay U.S. $302 Million to Resolve Allegations That a Subsidiary Sold Misbranded Test Kits 2Health News:Quest Diagnostics to Pay U.S. $302 Million to Resolve Allegations That a Subsidiary Sold Misbranded Test Kits 3Health News:Quest Diagnostics to Pay U.S. $302 Million to Resolve Allegations That a Subsidiary Sold Misbranded Test Kits 4Health News:UCSF, Stanford Study Reveals Neural Networks Targeted in Brain Diseases 2Health News:UCSF, Stanford Study Reveals Neural Networks Targeted in Brain Diseases 3Health News:UCSF, Stanford Study Reveals Neural Networks Targeted in Brain Diseases 4Health News:TopBestPennyStocks.com Issues Technical Trade Alerts on Hot Stocks in the Market Today: CAST, VM, NFLX, PFE, AA, & COF 2Health News:Helping hand of hybrid surgery benefits colorectal patients 2
... Merlin is a superior full-color, auto-focus, ... vision user in mind, Merlin enables the ... black and white, high contrast positive or ... video magnifier, this optional feature enables the ...
... purpose incubators designed to provide ... uniformity required for the most ... microprocessor controlled incubators feature push-button ... digital display, and built-in over-temperature ...
... Precision Economy Incubators available in five different ... of 1.4 cu. Ft. (39 liters), 2.5 ... ft. (129 liters. Equally important, Precision Economy ... excellent temperature sensitivity, stability, and uniformity. As ...
Aspheric diagnostic lens. 90D...
Medicine Products: